Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Presage, AstraZeneca Partner on Immuno-Oncology Drugs | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Presage, AstraZeneca Partner on Immuno-Oncology Drugs

Presage's platform will be used in translational analysis to evaluate investigational bispecific antibody combinations.

By: Anthony Vecchione

Presage Biosciences, a translational oncology company that uses CIVO and spatial molecular profiling to understand drug response in the tumor microenvironment (TME), entered an agreement with AstraZeneca to evaluate several investigational bispecific antibody combinations in samples taken from head and neck cancer patients. The work will contribute to advancing AstraZeneca’s portfolio of immuno-oncology agents looking to harness the immune system against cancer.

Earlier this month, Presage presented results from a Phase 0 study evaluating Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) alone and in combination with other immune-oncology agents in both soft tissue sarcoma and head and neck cancer. Study data highlight the importance of evaluating novel therapies in patient tumors and revealed a contradiction between results from in-vivo animal studies versus results in the intact TME.

Rich Klinghoffer, CEO of Presage, said, “Prior studies have demonstrated that the CIVO platform provides accurate guidance about the therapeutic potential of novel agents in the only context that matters: Fully intact patient tumors. We are very pleased to be working with an innovator like AstraZeneca and supporting their quest to discover, develop, and deliver transformative medicines to patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics